An azido-avermectin analog [4"a-(4-azidosal-icylamido-e-caproylamido-fi-alanylamido)-4"-deoxyavermectin B18; azido-AVMJ was synthesized and used to photoaffinity label avermectin binding sites present in the membranes of Caenorhabditis elegans and Drosophila melanogaster. Azido-AVM was biologically active and behaved like a competitive inhibitor of [3lHlivermectin binding to C. elegans membranes (K; = 0.2 nM). Radiolabeled azido-AVM bound specifically and with high affinity to C. elegans membranes (Kd = 0.14 nM) and, upon photoactivation, became covalently linked to three C. elegans polypeptides of 53, 47, and 8 kDa. Photoaffinity labeling of a membrane preparation from D.
The avermectins are a family of macrocyclic lactones isolated as natural fermentation products from Streptomyces avermitilis (1, 2) . Ivermectin (22,23-dihydroavermectin BIa) is a semisynthetic avermectin analog with unprecedented efficacy and breadth of spectrum against nematode and arthropod parasites. Since its introduction in 1981, it has had a tremendous impact on veterinary health (3) (4) (5) and more recently on human health (6, 7) . It has been approved for prophylactic use against Dirofilaria immitis, the causative agent of heartworm disease in dogs, and is widely used for the treatment of livestock against a variety of intestinal nematodes. It is currently the drug of choice for the control and prevention of human onchocerciasis, commonly known as river blindness, a debilitating tropical disease that affects an estimated 18 million people in Africa, Latin America, and the Middle East. Because the avermectins are without toxic side effects and are efficacious miticidal and insecticidal compounds (8, 9) , they also have been developed for use in crop protection programs. Although the mode of action of avermectins in target species is not completely understood, they cause an increase in membrane permeability to chloride ions that results in paralysis (10) . Specific, high-affinity avermectin binding sites have been identified and characterized in the free-living nematode, Caenorhabditis elegans (11, 12) . A clear correlation exists between the binding affinities for C. elegans membranes and in vivo efficacy of a series of avermectin analogs, indicating that the binding site is physiologically important. Specific avermectin binding sites also have been identified in mammalian brain tissue; however, the affinity is lower by a factor of -100 in brain, which may account for the relatively low mammalian toxicity of this family of compounds (11) . Electrophysiological and biochemical studies support a role for the avermectins in the modulation of y-aminobutyrate-gated chloride channels in vertebrate neuronal tissues (13) (14) (15) (16) . In contrast, the primary site of action of the avermectins in nematodes and insects appears to be a non-y-aminobutyrate-gated chloride channel (17) (18) (19) .
A detailed understanding of the mechanism of action of ivermectin in nematodes and insects could be obtained through biochemical isolation and characterization of the proteins possessing the drug binding sites. Purification of the biologically active receptor is not trivial, due to the low abundance of the receptor in invertebrate tissues and the nearly irreversible binding of ivermectin to the C. elegans tTo whom reprint requests should be addressed.
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Proc. Natl. Acad. Sci. USA 89 (1992) 4169 receptor. Covalent modification of the receptor proteins with a photoactive analog of the drug would facilitate purification of these proteins under denaturing conditions. In this report we describe the identification of specific avermectin-binding proteins from a nematode (C. elegans) and an insect (Drosophila melanogaster) by photoaffinity labeling with a radioiodinated azidoavermectin analog. C. elegans Cultures. All studies described in this paper were performed with tissue extracts prepared from the wild-type C. elegans strain N2. Worms were grown in liquid culture in a 150-liter fermentor with Escherichia coli as a source of food. Details of the conditions used for large-scale cultivation and harvesting will be described elsewhere (K. Gbewonyo, S.P.R., L. Lister, B. Burgess, M. Einstein, D. Cully, and B. Buckland, unpublished work).
MATERIALS AND METHODS
Worms were purified by flotation on 35% sucrose (21) and washed extensively with 0.1 M NaCl prior to breakage with a Manton-Gaulin homogenizer. Sucrose-purified worms (500 g) were homogenized in 2 liters of 50 mM Hepes (pH 7) containing 1 mM ethylenediaminetetraacetic acid (EDTA), 0.2 mM phenylmethanesulfonyl fluoride, leupeptin at 0.5 ,g/ml, and pepstatin at 0.7 ,tg/ml. The homogenate was centrifuged at 1000 x g and the pellet was discarded. The supernatant was centrifuged at 28,000 x g and the resultant pellet was resuspended at a final protein concentration of 5 mg/ml in 50 mM Hepes (pH 7) containing the protease inhibitors listed above. Membrane suspensions were dialyzed extensively against the same buffer prior to freezing at -700C.
The C. elegans motility assay used for assessing biological activity of avermectin analogs has been described (11) .
Solubilization of the Avermectin Binding Site. Frozen membranes were thawed and diluted with 50 mM Hepes (pH 7) to a final protein concentration of 2 mg/ml. Triton X-100 (Pierce) supplied as a 10% (vol/vol) solution was added to give a final detergent concentration of 0.5%. This mixture was stirred for 1 hr on ice and then centrifuged for 1 hr in a Ti 65 rotor (Beckman) at 100,000 x g. The 100,000 x g supernatant was filtered through a 0.22-,tm GV-X Millipore filter prior to use in binding assays or labeling experiments.
[31H]Ivermectin Binding Assay. For measurement of binding of [3H]ivermectin to C. elegans membranes or to a Triton X-100-soluble membrane protein preparation, =200 pug of protein was used per 1-ml assay. The standard binding assay (11) elegans motility assay. The LD95 values were 10 ng/ml and 3 ng/ml, respectively.
The IC50 for ivermectin was 0.2 nM and the IC50 for azido-AVM was 0.3 nM (Fig. 2A) (Fig.   2C ). The experiments described in Fig. 2 , as well as the C. elegans motility assay, were performed in the dark in order to avoid photoactivation of the azido-AVM analog.
1I25-Azido-AVM Binding. Saturable binding of 1251I-azido-AVM to a C. elegans 28,000 X g membrane preparation was demonstrated (Fig. 3A) . Scatchard analysis of the data gave a Kd for 125I-azido-AVM of 0.14 nM and a B. of 0.38 pmol/mg (Fig. 3A Inset) . These numbers agree closely with findings for [3H]ivermectin binding to C. elegans membranes (11).
Photoaffinity Labeling of C. elegans Avermectin Binding
Sites. Aliquots of the Triton X-100-solubilized C. elegans membrane proteins were assayed at each step of the binding and crosslinking protocol in order to ensure that the ratio of specific to nonspecific binding of 125I-azido-AVM to C. elegans proteins did not change at any one step in the experiment. Fig. 3B shows the result obtained when samples were incubated with the 125I-azido-AVM in the absence or presence of various concentrations of unlabeled ivermectin and then subjected to UV crosslinking. The profile resembled the competition curve seen in Fig. 2A, indicating Fig. 4 B and C . Fig. 4B shows on an autoradiogram the experimental result obtained and described in Fig. 3B . In the absence of unlabeled, competing ivermectin, three major proteins with estimated molecular masses of approximately 12, 47, and 53 kDa were labeled. As the amount of competing unlabeled ivermectin added during the incubation with 125I-azido-AVM was increased (lanes 2-5), the labeling of the bands with 125I-azido-AVM was diminished. These results demonstrate that the three bands were labeled specifically and were indicative of the high-affinity binding site. The smaller affinity-labeled protein appearing at 12 kDa on this gradient gel was analyzed in an SDS/20% polyacrylamide gel and found to be closer to 8 kDa (data not shown).
Fig . 4C shows the autoradiogram from a similar experiment in which the ability of ivermectin to block affinity labeling of the receptor by 125I-azido-AVM was compared with the effect of octahydroavermectin, the inactive analog. While ivermectin competed effectively for the avermectin binding site and prevented labeling by 125I-azido-AVM, octahydroavermectin was ineffective. This finding is consistent with previously established octahydroavermectin binding data (11) and further substantiates the claim that the three C. elegans proteins labeled by 125I-azido-AVM were indeed labeled specifically and represent the high-affinity binding site.
Photoaffinity Labeling of D. melanogaster Avermectin Binding Sites. Affinity labeling of Drosophila head membranes was performed with 0.26 nM 1251I-azido-AVM in the absence or presence of 10 nM unlabeled ivermectin. Fig. 5 shows that a single major protein with estimated molecular mass of 47 kDa was labeled in a specific fashion. A minor protein band near the bottom of the gel (15 kDa) was also labeled. On polypeptides from C. elegans represent degradative products of a single binding protein, individual subunits of a heterotrimeric receptor complex, or tissue-specific forms of highaffinity avermectin-binding proteins could be determined by isolating and sequencing each product. The apparent number of avermectin binding sites present on Drosophila membranes was 5-10 times higher than that in the C. elegans tissue preparations and probably reflects the enriched population of neuronal cell membranes in the Drosophila head homogenate.
Prior to initiating the affinity labeling approach, we directed substantial effort toward purification of the biologically active C. elegans receptor in its native state. Synthesis of the avermectin analogs and affinity resins used in this approach will be discussed elsewhere (P.T.M., S.P.R., E.C.H., J.M.S., M. Fisher, and H.M., unpublished work). However, covalent tagging of the C. elegans avermectin binding site with 125I-azido-AVM has eliminated the need to purify under nondenaturing conditions and has greatly increased the probability of purifying the binding-site proteins to homogeneity.
The cloning and structure determination of this binding site, which presumably is part of an avermectin-sensitive chloride channel, should prove useful for understanding of the mode of action of the avermectins. Information gathered from such studies may facilitate the discovery or design of 
